Table 2 Correlation between the p53R2 expression and clinicopathological variables in NPC patients
From: p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma
Variable | Expression of p53R2 | |||
|---|---|---|---|---|
All cases | Low | High | P value | |
Gender | 0.217 | |||
Female | 57 | 39 (68.4%) | 18 (31.6%) | |
Male | 144 | 85 (59.0%) | 59 (41.0%) | |
Age | 0.593 | |||
≤45.89a | 104 | 66 (63.5%) | 38 (36.5%) | |
>45.89 | 97 | 58 (59.8%) | 39 (40.2%) | |
Clinical stage | 0.450 | |||
I-II | 39 | 22(56.4%) | 17 (43.6%) | |
III-IV | 162 | 102(63.0%) | 60 (37.0%) | |
T stage | 0.043 | |||
T1 + T2 | 64 | 33 (51.6%) | 31 (48.4%) | |
T3 + T4 | 137 | 91 (66.4%) | 46 (33.6%) | |
N stage | 0.469 | |||
N0 | 28 | 19 (67.9%) | 9 (32.1%) | |
N1 + N2 + N3 | 173 | 105 (60.7%) | 68 (39.3%) | |
Therapyb | 0.205 | |||
Regimen 1 | 50 | 34 (68.0%) | 16 (32.0%) | |
Regimen 2 | 72 | 46 (63.9%) | 26 (36.1%) | |
Regimen 3 | 31 | 14 (45.2%) | 17 (54.8%) | |
Regimen 4 | 48 | 30 (62.5%) | 18 (37.5%) | |
Relapse | 0.543 | |||
Yes | 30 | 20 (66.7%) | 10 (33.3%) | |
No | 171 | 104 (60.8%) | 67 (39.2%) | |